Ostalo

https://doi.org/10.20471/acc.2018.57.01.27

Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017

Branimir Jakšić ; Merkur University Hospital, School of Medicine, University of Zagreb, Zagreb, Croatia
Vlatko Pejša ; School of Medicine, University of Zagreb, Zagreb, Croatia
Slobodanka Ostojić-Kolonić ; Merkur University Hospital, School of Medicine, University of Zagreb, Zagreb, Croatia
Ika Kardum-Skelin ; Merkur University Hospital, School of Medicine, University of Zagreb, Zagreb, Croatia
Sandra Bašić-Kinda ; Dubrava University Hospital, School of Medicine, University of Zagreb, Zagreb, Croatia
Božena Coha ; Zagreb University Hospital Center, School of Medicine, University of Zagreb, Zagreb, Croatia
Velka Gverić-Krečak ; Dr Josip Benčević General Hospital, Slavonski Brod, Croatia
Radovan Vrhovac ; Dubrava University Hospital, School of Medicine, University of Zagreb, Zagreb, Croatia
Ozren Jakšić ; School of Medicine, University of Zagreb, Zagreb, Croatia
Igor Aurer ; Dubrava University Hospital, School of Medicine, University of Zagreb, Zagreb, Croatia
Jasminka Sinčić-Petričević ; Šibenik General Hospital, Šibenik, Croatia
Antica Načinović-Duletić ; Osijek University Hospital Center, Faculty of Medicine, Josip Juraj University of Osijek, Osijek, Croatia
Damir Nemet ; Dubrava University Hospital, School of Medicine, University of Zagreb, Zagreb, Croatia

Sažetak

Recent developments in the diagnosis and treatment of chronic lymphocytic leukemia (B-CLL) have led to change of approach in clinical practice. New treatments have been approved based on the results of randomized multicenter trials for first line and for salvage therapy, and the results of numerous ongoing clinical trials are permanently providing new answers and further refining of therapeutic strategies. This is paralleled by substantial increase in understanding the disease genetics due to major advances in the next generation sequencing (NGS) technology. We define current position of the Croatian Cooperative Group for Hematologic Disease on diagnosis and treatment of CLL in the transition from chemo-immunotherapy paradigm into a new one that is based on new diagnostic stratification and unprecedented therapeutic results of B-cell receptor inhibitors (BRI) and Bcl-2 antagonists. This is a rapidly evolving field as a great number of ongoing clinical trials constantly accumulate and provide new knowledge. We believe that novel therapy research including genomic diagnosis is likely to offer new options that will eventually lead to time limited therapies without chemotherapy and more effective clinical care for B-CLL based on individualized precision medicine.

Ključne riječi

Chronic lymphocytic leukemia; Practice guidelines as topic; Precision medicine; Croatia; KROHEM

Hrčak ID:

202242

URI

https://hrcak.srce.hr/202242

Datum izdavanja:

1.3.2018.

Podaci na drugim jezicima: hrvatski

Posjeta: 5.398 *